Rekombinanter PTK7 (Cofetuzumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter PTK7 (Cofetuzumab Biosimilar) Antikörper (ABIN7581642)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab)
-
Sequenz
- QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLEWIGV ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSRLRSED TAVYYCARGN SYFYALDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG,EIVLTQSPAT LSLSPGERAT LSCRASESVD SYGKSFMHWY QQKPGQAPRL LIYRASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
Produktmerkmale
- Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: PTK7 regulators
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- PTK7 (Cofetuzumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- Q13308-1
Target
-